ESSA Pharma Inc. (NASDAQ:EPIX) Plans $1.69 -- Dividend

Key Points

• ESSA Pharma Inc. declared a dividend of $1.69 per share on August 18th, with a payable date of August 22nd for stockholders of record as of August 19th.
• As of midday trading on Monday, the stock price for NASDAQ:EPIX was $1.91, with a market cap of $90.36 million.
• ESSA Pharma reported earnings of ($0.09) per share for the recent quarter, exceeding analysts' estimates and projecting an EPS of -0.42 for the current fiscal year.

ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI announced a -- dividend on Tuesday, August 5th, Wall Street Journal reports. Stockholders of record on Tuesday, August 19th will be paid a dividend of 1.69 per share on Friday, August 22nd. The ex-dividend date is Monday, August 25th.

ESSA Pharma Stock Up 0.5%

Shares of ESSA Pharma stock traded up $0.01 during midday trading on Friday, hitting $1.93. The company's stock had a trading volume of 3,030,599 shares, compared to its average volume of 332,282. The firm has a market capitalization of $91.31 million, a P/E ratio of -3.45 and a beta of 1.55. ESSA Pharma has a 1-year low of $1.40 and a 1-year high of $7.88. The stock has a 50-day simple moving average of $1.82 and a 200-day simple moving average of $1.72.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. As a group, sell-side analysts predict that ESSA Pharma will post -0.42 earnings per share for the current year.

Institutional Trading of ESSA Pharma

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in ESSA Pharma by 10,153,775.0% during the fourth quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock valued at $1,454,000 after purchasing an additional 812,302 shares during the last quarter. Two Sigma Investments LP acquired a new stake in ESSA Pharma during the fourth quarter valued at $378,000. Jane Street Group LLC acquired a new stake in ESSA Pharma during the fourth quarter valued at $82,000. Cubist Systematic Strategies LLC bought a new position in ESSA Pharma during the fourth quarter valued at about $47,000. Finally, Squarepoint Ops LLC bought a new position in ESSA Pharma during the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 75.12% of the company's stock.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.